Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens
Abstract Background Etravirine (ETR), a non-nucleoside reverse transcriptase inhibitor (NNRTI) available in France since 2006, is indicated for antiretroviral-experienced HIV-infected adults, in combination with a ritonavir-boosted protease inhibitor (PI). To assess its clinical impact in routine ca...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2018-07-01
|
| シリーズ: | BMC Infectious Diseases |
| 主題: | |
| オンライン・アクセス: | http://link.springer.com/article/10.1186/s12879-018-3231-5 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
